Cervical Spine ImmobilisationNCT07802522
Hyperangulated Video Laryngoscopes Used for Intubation With Simultaneous Cervical Spine Immobilization
A study testing Airway management in people with Cervical Spine Immobilisation and Airway Management, run by Uniwersytet Radomski im. Kazimierza Pułaskiego at 1 site in Poland.
Trial summary
This study will evaluate four videolaryngoscopes used for intubation of patients with cervical spine immobilization. Two hundred adult patients (females and males) with ASA (American Society of Anesthesiologist) status 1-3 will be scheduled for elective laparoscopic surgery at the Mazowiecki Szpital Specjalistyczny in… Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Cervical Spine Immobilisation, Airway Management, Difficult Airway
- What is being tested?
- Airway management
- Type of treatment
- Medical device
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 200 participants
- Where
- 1 sitePoland
- Study dates
- 31 Aug 2026to 31 Oct 2026
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- ASA status 1-3
- aged over 18 years old
- male and female
- laparoscopic surgery
Who cannot join
- known difficult laryngoscopy
- difficult face mask ventilation
- aged under 18 years old
- previous history of awake tracheal intubation
- patients with BMI > 30 kg m-2
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
About this study
Official title: Evaluation of the VisionPro Hyperangulated Videolaryngoscope During Intubation of Patients With Simultaneous Cervical Spine Immobilisation - a Randomized Clinical Trial
This study will evaluate four videolaryngoscopes used for intubation of patients with cervical spine immobilization. Two hundred adult patients (females and males) with ASA (American Society of Anesthesiologist) status 1-3 will be scheduled for elective laparoscopic surgery at the Mazowiecki Szpital Specjalistyczny in Radom, Poland. Patients with known difficult laryngoscopy, difficult face mask ventilation, with previous history of awake tracheal intubation, those aged under 18 years or patients with BMI > 30 kg m-2 will be excluded from the study. All patients will receive oral premedication with 7.5 mg midazolam 30 minutes before the start of anaesthesia. A standard monitoring will be applied. This consists of ECG, NIBP (non-invasive blood pressure), SpO2, TOF (train-of-four) and volatile anaesthetic concentration. In order to achieve cervical spine immobilization, a Patriot® cervical collar (Össur hf., Reykjavik, Iceland) will be applied. The size of the collar will be adjusted to the patient's anatomy. Furthermore, the cervical collar will be fixed to allow a minimal mouth opening of 20 mm. All patients will be placed in a neutral position and will be pre-oxygenated with FiO2 1.0 for three minutes prior to induction. Anaesthesia will be induced with fentanyl (1-2 µg ml-1) and propofol (2-3 mg ml-1). Rocuronium (0.6 mg ml-1) will be used as a neuromuscular blocking agent. Adequate neuromuscular block will be confirmed and controlled throughout the procedure with TOF Watch (Organon, Dublin, Ireland). A cuffed, size 7.5 tracheal tube with stylet (Sumi, Sulejówek, Poland) will be used for intubation. A single-use hyperangulated blade will be used in all studied devices. Correct placement of the tracheal tube will be confirmed by videolaryngoscopy, capnography and chest auscultation. All patients will be anaesthetised by experienced consultant anaesthetists with over 10 years of clinical practice after completion of specialist training. Furthermore, all anaesthetists participating in the study will be trained beforehand with all VLs used until they feel competent. Only two intubation attempts with a studied videolaryngoscope will be allowed. A single attempt will be limited to 60 seconds. A failure is defined as an attempt which lasts more than 60 seconds, when saturation drops below 90%, after two unsuccessful attempts, when airway injury or bronchospasm occurrs. A single-digit number will be allocated to each of the studied videolaryngoscopes: 1 for the C-MAC PM, 2 for the McGrath, 3 for the VisionPro and 4 for the AceScope. A single sheet of paper containing printed number will be placed in an opaque envelope. Then they will be assigned to the participating anaesthetist by computer-generated randomization. The SPSS 29.0 software (IBM, Armonk, NY, USA) will be used for allocation. Furthermore, patients will be blinded to randomization.
Read the detailed description
This study will evaluate four videolaryngoscopes used for intubation of patients with cervical spine immobilization. Two hundred adult patients (females and males) with ASA (American Society of Anesthesiologist) status 1-3 will be scheduled for elective laparoscopic surgery at the Mazowiecki Szpital Specjalistyczny in Radom, Poland. Patients with known difficult laryngoscopy, difficult face mask ventilation, with previous history of awake tracheal intubation, those aged under 18 years or patients with BMI > 30 kg m-2 will be excluded from the study. All patients will receive oral premedication with 7.5 mg midazolam 30 minutes before the start of anaesthesia. A standard monitoring will be applied. This consists of ECG, NIBP (non-invasive blood pressure), SpO2, TOF (train-of-four) and volatile anaesthetic concentration. In order to achieve cervical spine immobilization, a Patriot® cervical collar (Össur hf., Reykjavik, Iceland) will be applied. The size of the collar will be adjusted to the patient's anatomy. Furthermore, the cervical collar will be fixed to allow a minimal mouth opening of 20 mm. All patients will be placed in a neutral position and will be pre-oxygenated with FiO2 1.0 for three minutes prior to induction. Anaesthesia will be induced with fentanyl (1-2 µg ml-1) and propofol (2-3 mg ml-1). Rocuronium (0.6 mg ml-1) will be used as a neuromuscular blocking agent. Adequate neuromuscular block will be confirmed and controlled throughout the procedure with TOF Watch (Organon, Dublin, Ireland). A cuffed, size 7.5 tracheal tube with stylet (Sumi, Sulejówek, Poland) will be used for intubation. A single-use hyperangulated blade will be used in all studied devices. Correct placement of the tracheal tube will be confirmed by videolaryngoscopy, capnography and chest auscultation. All patients will be anaesthetised by experienced consultant anaesthetists with over 10 years of clinical practice after completion of specialist training. Furthermore, all anaesthetists participating in the study will be trained beforehand with all VLs used until they feel competent. Only two intubation attempts with a studied videolaryngoscope will be allowed. A single attempt will be limited to 60 seconds. A failure is defined as an attempt which lasts more than 60 seconds, when saturation drops below 90%, after two unsuccessful attempts, when airway injury or bronchospasm occurrs. A single-digit number will be allocated to each of the studied videolaryngoscopes: 1 for the C-MAC PM, 2 for the McGrath, 3 for the VisionPro and 4 for the AceScope. A single sheet of paper containing printed number will be placed in an opaque envelope. Then they will be assigned to the participating anaesthetist by computer-generated randomization. The SPSS 29.0 software (IBM, Armonk, NY, USA) will be used for allocation. Furthermore, patients will be blinded to randomization.
The primary outcomes are the intubation time (Ti) and the first-attempt success. The Ti is defined as the time from picking up the videolaryngoscope until the correct placement of the tracheal tube will be confirmed by capnography. A stop watch of a mobile phone (Apple, Cupertino, CA, USA) will be used to measure Ti. The secondary outcomes include the ease-of-use and the time required to achieve the glottic view (Tg). The former will be evaluated using the NRS (Numerical Rating Scale). This is an eleven-point scale, i.e. from 0 to 10, and the score 0 denotes a very difficult and complicated to use device while 10 corresponds to an user-friendly equipment. The Tg is defined as the time from picking up the videolaryngoscope until the optimal entry-to-the-larynx view is achieved.
Collected data will be analysed using Statistica 14.0 (TIBCO Software, Palo Alto, CA, USA) and Microsoft Office Excel 2021 spreadsheet (Microsoft, Redmond, WA, USA). The Wilcoxon signed-rank test and the paired Student t-test will be used for data analysis. Continuous variables will be presented either as mean ± SD (standard deviation) or median (IQR - interquartile range) for non-normally distributed data. The Kolmogorov-Smirnov test will determine whether the analysed variables matches the characteristics of a normal distribution. We assume that the overall success rate of intubation in obese patients will be 90% (α = 0.05, 2-sided, β = 0.1, 95% CI). The calculated sample size requires 195 participants and the final adjusted sample size will be 200 patients to compensate for dropouts. A p-value of less than 0.05 (p < 0.05) is considered statistically significant.
- Being tested
- Airway management
- Keywords
- videolaryngoscope, difficult airway, hyperangulated blade, cervical spine immobilisation, intubation
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Airway managementDevice
Device used for intubation
| Study group | Role | What they receive |
|---|---|---|
| VisionPro | Experimental | Device used for intubation Receives: Device: Airway management |
| C-MAC | Active comparator | Device used for intubation Receives: Device: Airway management |
| McGrath | Active comparator | Device used for intubation Receives: Device: Airway management |
| AceScope | Active comparator | Device used for intubation Receives: Device: Airway management |
What is being measured
The primary outcome is the main question the study is designed to answer.
First-attempt success
This is the percentage of successful tracheal tube placement at the first attempt.
Measured: From date of randomization until the date of first documented progression, assessed up to 10 months
Intubation time
The intubation time is defined as the time from picking up the videolaryngoscope until the correct placement of the tracheal tube has been confirmed by capnography. A stop watch of a mobile phone (Apple, Cupertino, CA, USA) will be used to measure the intubation time.
Measured: From date of randomization until the date of first documented progression, assessed up to 10 months
Secondary outcomes (2)
User-friendliness of the device used
It will be evaluated using the Numerical Rating Scale (NRS). This is an eleven-point scale, i.e. from 0 to 10, and regarding the ease-of-use 0 denotes a very difficult and complicated to use device while 10 corresponds to an user-friendly equipment.
Measured: From date of randomization until the date of first documented progression, assessed up to 10 months
The time required to achieve the glottic view
This is defined as the time from picking up the videolaryngoscope until the optimal entry-to-the-larynx view has been achieved. A stop watch of a mobile phone (Apple, Cupertino, CA, USA) will be used to measure this parameter.
Measured: From date of randomization until the date of first documented progression, assessed up to 10 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted3 Sep 2026
- Study start31 Aug 2026
- Primary completion31 Oct 2026 (estimated)
- Study completion31 Oct 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Cervical Spine ImmobilisationStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind
- Who is masked
- Investigator
- Enrolment
- 200 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Uniwersytet Radomski im. Kazimierza Pułaskiego
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07802522
- Sponsor's protocol ID
- 2/2026
- Status last verified
- Aug 2026
- First submitted
- 31 Aug 2026
- Last updated
- 3 Sep 2026
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 3 Sep 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Evaluation of the VisionPro Hyperangulated Videolaryngoscope During Intubation of Patients With Simultaneous Cervical Spine Immobilisation - a Randomized Clinical Trial
- ClinicalTrials.gov ID
- NCT07802522
- Acronym / sponsor ID
- 2/2026
- Keywords
- videolaryngoscope, difficult airway, hyperangulated blade, cervical spine immobilisation, intubation
- Study type
- Interventional
- Recruitment status
- Enrolling by invitation
- Enrolment
- 200 participants (estimated)
- Lead sponsor
- Uniwersytet Radomski im. Kazimierza PułaskiegoUniversity, hospital or other
- Study start
- 31 Aug 2026 (actual)
- Primary completion
- 31 Oct 2026 (estimated)
- Study completion
- 31 Oct 2026 (estimated)
- First posted
- 3 Sep 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This study will evaluate four videolaryngoscopes used for intubation of patients with cervical spine immobilization. Two hundred adult patients (females and males) with ASA (American Society of Anesthesiologist) status 1-3 will be scheduled for elective laparoscopic surgery at the Mazowiecki Szpital Specjalistyczny in Radom, Poland. Patients with known difficult laryngoscopy, difficult face mask ventilation, with previous history of awake tracheal intubation, those aged under 18 years or patients with BMI > 30 kg m-2 will be excluded from the study. All patients will receive oral premedication with 7.5 mg midazolam 30 minutes before the start of anaesthesia. A standard monitoring will be applied. This consists of ECG, NIBP (non-invasive blood pressure), SpO2, TOF (train-of-four) and volatile anaesthetic concentration. In order to achieve cervical spine immobilization, a Patriot® cervical collar (Össur hf., Reykjavik, Iceland) will be applied. The size of the collar will be adjusted to the patient's anatomy. Furthermore, the cervical collar will be fixed to allow a minimal mouth opening of 20 mm. All patients will be placed in a neutral position and will be pre-oxygenated with FiO2 1.0 for three minutes prior to induction. Anaesthesia will be induced with fentanyl (1-2 µg ml-1) and propofol (2-3 mg ml-1). Rocuronium (0.6 mg ml-1) will be used as a neuromuscular blocking agent. Adequate neuromuscular block will be confirmed and controlled throughout the procedure with TOF Watch (Organon, Dublin, Ireland). A cuffed, size 7.5 tracheal tube with stylet (Sumi, Sulejówek, Poland) will be used for intubation. A single-use hyperangulated blade will be used in all studied devices. Correct placement of the tracheal tube will be confirmed by videolaryngoscopy, capnography and chest auscultation. All patients will be anaesthetised by experienced consultant anaesthetists with over 10 years of clinical practice after completion of specialist training. Furthermore, all anaesthetists participating in the study will be trained beforehand with all VLs used until they feel competent. Only two intubation attempts with a studied videolaryngoscope will be allowed. A single attempt will be limited to 60 seconds. A failure is defined as an attempt which lasts more than 60 seconds, when saturation drops below 90%, after two unsuccessful attempts, when airway injury or bronchospasm occurrs. A single-digit number will be allocated to each of the studied videolaryngoscopes: 1 for the C-MAC PM, 2 for the McGrath, 3 for the VisionPro and 4 for the AceScope. A single sheet of paper containing printed number will be placed in an opaque envelope. Then they will be assigned to the participating anaesthetist by computer-generated randomization. The SPSS 29.0 software (IBM, Armonk, NY, USA) will be used for allocation. Furthermore, patients will be blinded to randomization.
Detailed description
This study will evaluate four videolaryngoscopes used for intubation of patients with cervical spine immobilization. Two hundred adult patients (females and males) with ASA (American Society of Anesthesiologist) status 1-3 will be scheduled for elective laparoscopic surgery at the Mazowiecki Szpital Specjalistyczny in Radom, Poland. Patients with known difficult laryngoscopy, difficult face mask ventilation, with previous history of awake tracheal intubation, those aged under 18 years or patients with BMI > 30 kg m-2 will be excluded from the study. All patients will receive oral premedication with 7.5 mg midazolam 30 minutes before the start of anaesthesia. A standard monitoring will be applied. This consists of ECG, NIBP (non-invasive blood pressure), SpO2, TOF (train-of-four) and volatile anaesthetic concentration. In order to achieve cervical spine immobilization, a Patriot® cervical collar (Össur hf., Reykjavik, Iceland) will be applied. The size of the collar will be adjusted to the patient's anatomy. Furthermore, the cervical collar will be fixed to allow a minimal mouth opening of 20 mm. All patients will be placed in a neutral position and will be pre-oxygenated with FiO2 1.0 for three minutes prior to induction. Anaesthesia will be induced with fentanyl (1-2 µg ml-1) and propofol (2-3 mg ml-1). Rocuronium (0.6 mg ml-1) will be used as a neuromuscular blocking agent. Adequate neuromuscular block will be confirmed and controlled throughout the procedure with TOF Watch (Organon, Dublin, Ireland). A cuffed, size 7.5 tracheal tube with stylet (Sumi, Sulejówek, Poland) will be used for intubation. A single-use hyperangulated blade will be used in all studied devices. Correct placement of the tracheal tube will be confirmed by videolaryngoscopy, capnography and chest auscultation. All patients will be anaesthetised by experienced consultant anaesthetists with over 10 years of clinical practice after completion of specialist training. Furthermore, all anaesthetists participating in the study will be trained beforehand with all VLs used until they feel competent. Only two intubation attempts with a studied videolaryngoscope will be allowed. A single attempt will be limited to 60 seconds. A failure is defined as an attempt which lasts more than 60 seconds, when saturation drops below 90%, after two unsuccessful attempts, when airway injury or bronchospasm occurrs. A single-digit number will be allocated to each of the studied videolaryngoscopes: 1 for the C-MAC PM, 2 for the McGrath, 3 for the VisionPro and 4 for the AceScope. A single sheet of paper containing printed number will be placed in an opaque envelope. Then they will be assigned to the participating anaesthetist by computer-generated randomization. The SPSS 29.0 software (IBM, Armonk, NY, USA) will be used for allocation. Furthermore, patients will be blinded to randomization.
The primary outcomes are the intubation time (Ti) and the first-attempt success. The Ti is defined as the time from picking up the videolaryngoscope until the correct placement of the tracheal tube will be confirmed by capnography. A stop watch of a mobile phone (Apple, Cupertino, CA, USA) will be used to measure Ti. The secondary outcomes include the ease-of-use and the time required to achieve the glottic view (Tg). The former will be evaluated using the NRS (Numerical Rating Scale). This is an eleven-point scale, i.e. from 0 to 10, and the score 0 denotes a very difficult and complicated to use device while 10 corresponds to an user-friendly equipment. The Tg is defined as the time from picking up the videolaryngoscope until the optimal entry-to-the-larynx view is achieved.
Collected data will be analysed using Statistica 14.0 (TIBCO Software, Palo Alto, CA, USA) and Microsoft Office Excel 2021 spreadsheet (Microsoft, Redmond, WA, USA). The Wilcoxon signed-rank test and the paired Student t-test will be used for data analysis. Continuous variables will be presented either as mean ± SD (standard deviation) or median (IQR - interquartile range) for non-normally distributed data. The Kolmogorov-Smirnov test will determine whether the analysed variables matches the characteristics of a normal distribution. We assume that the overall success rate of intubation in obese patients will be 90% (α = 0.05, 2-sided, β = 0.1, 95% CI). The calculated sample size requires 195 participants and the final adjusted sample size will be 200 patients to compensate for dropouts. A p-value of less than 0.05 (p < 0.05) is considered statistically significant.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind (investigator)
- Number of arms
- 4
| Arm | Type | Receives |
|---|---|---|
| VisionPro | Experimental | Device: Airway managementDevice used for intubation |
| C-MAC | Active comparator | Device: Airway managementDevice used for intubation |
| McGrath | Active comparator | Device: Airway managementDevice used for intubation |
| AceScope | Active comparator | Device: Airway managementDevice used for intubation |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (4 listed)
- ASA status 1-3
- aged over 18 years old
- male and female
- laparoscopic surgery
Key exclusion criteria (5 listed)
- known difficult laryngoscopy
- difficult face mask ventilation
- aged under 18 years old
- previous history of awake tracheal intubation
- patients with BMI > 30 kg m-2
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Airway managementDevice used for intubation | Device | AceScope, C-MAC, McGrath, VisionPro |
Primary outcome
First-attempt success
Time frame: From date of randomization until the date of first documented progression, assessed up to 10 months
This is the percentage of successful tracheal tube placement at the first attempt.
Intubation time
Time frame: From date of randomization until the date of first documented progression, assessed up to 10 months
The intubation time is defined as the time from picking up the videolaryngoscope until the correct placement of the tracheal tube has been confirmed by capnography. A stop watch of a mobile phone (Apple, Cupertino, CA, USA) will be used to measure the intubation time.
2 secondary outcomes
User-friendliness of the device used
Time frame: From date of randomization until the date of first documented progression, assessed up to 10 months
The time required to achieve the glottic view
Time frame: From date of randomization until the date of first documented progression, assessed up to 10 months
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 3 Sep 2026.
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Airway management in people with Cervical Spine Immobilisation and Airway Management, run by Uniwersytet Radomski im. Kazimierza Pułaskiego at 1 site in Poland.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: enrolling by invitation, as of the sponsor's last update on 3 Sep 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Poland. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
First-attempt success (time frame: From date of randomization until the date of first documented progression, assessed up to 10 months). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 3 Sep 2026.